<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02482155</url>
  </required_header>
  <id_info>
    <org_study_id>070(I)HO14386</org_study_id>
    <secondary_id>CRO-PK-14-291</secondary_id>
    <nct_id>NCT02482155</nct_id>
  </id_info>
  <brief_title>Ibuprofen (MOMENT ACT ANALGESIC Granules) Pharmacokinetic Study</brief_title>
  <official_title>Pharmacokinetic Study of a Single Oral Administration of MOMENT ACT ANALGESIC Granules for Oral Solution to Healthy Volunteers Under Fasting Conditions Single Centre, Single Dose, Open-label, Bioavailability Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aziende Chimiche Riunite Angelini Francesco S.p.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cross Research S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aziende Chimiche Riunite Angelini Francesco S.p.A</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study was to evaluate the pharmacokinetic (PK) profile of ibuprofen&#xD;
      after oral administration of a single dose of MOMENT ACT ANALGESIC granules to healthy male&#xD;
      and female subjects, under fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of ibuprofen</measure>
    <time_frame>0, 3, 5, 10, 15, 20, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of ibuprofen</measure>
    <time_frame>0, 3, 5, 10, 15, 20, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax) of ibuprofen</measure>
    <time_frame>0, 3, 5, 10, 15, 20, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal elimination rate constant (Î»z) of ibuprofen</measure>
    <time_frame>0, 3, 5, 10, 15, 20, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal elimination half-life (t1/2,z) of ibuprofen</measure>
    <time_frame>0, 3, 5, 10, 15, 20, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Lag-time from the dosing time point prior to the first measurable plasma concentration (tlag) of ibuprofen</measure>
    <time_frame>0, 3, 5, 10, 15, 20, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to the first ibuprofen plasma concentration of 5 ug/mL (ton5)</measure>
    <time_frame>0, 3, 5, 10, 15, 20, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to the first ibuprofen plasma concentration of 10 ug/mL (ton10)</measure>
    <time_frame>0, 3, 5, 10, 15, 20, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse effects</measure>
    <time_frame>up to 24 hours after administration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ibuprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ibuprofen 400 mg granules, oral solution, single administration under fasting conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>ibuprofen 400 mg single dose oral solution</description>
    <arm_group_label>ibuprofen</arm_group_label>
    <other_name>MOMENTACT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed consent: signed written informed consent before inclusion in the study;&#xD;
&#xD;
          2. Sex and age: females and males, 18-55 years old both inclusive;&#xD;
&#xD;
          3. Body Mass Index (BMI): 18.5-30 kg/m2 inclusive;&#xD;
&#xD;
          4. Vital signs: systolic blood pressure (SBP) 100-139 mmHg, diastolic blood pressure&#xD;
             (DBP) 50-89 mmHg, heart rate (HR) 50-90 bpm, measured after 5 min at rest in the&#xD;
             sitting position;&#xD;
&#xD;
          5. Full comprehension: ability to comprehend the full nature and purpose of the study,&#xD;
             including possible risks and side effects; ability to co-operate with the investigator&#xD;
             and to comply with the requirements of the entire study;&#xD;
&#xD;
          6. Contraception and fertility (females only): females of child-bearing potential must be&#xD;
             using at least one of the following reliable methods of contraception:&#xD;
&#xD;
               1. hormonal oral, implantable, transdermal, or injectable contraceptives for at&#xD;
                  least 2 months before the screening visit;&#xD;
&#xD;
               2. a non-hormonal intrauterine device or female condom with spermicide or&#xD;
                  contraceptive sponge with spermicide or diaphragm with spermicide or cervical cap&#xD;
                  with spermicide for at least 2 months before the screening visit;&#xD;
&#xD;
               3. a male sexual partner who agrees to use a male condom with spermicide;&#xD;
&#xD;
               4. a sterile sexual partner. Female participants of non-child-bearing potential or&#xD;
                  in post-menopausal status for at least 1 year will be admitted. For all female&#xD;
                  subjects, pregnancy test result must be negative at screening and day -1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Electrocardiogram (ECG) 12-leads (supine position): clinically significant&#xD;
             abnormalities;&#xD;
&#xD;
          2. Physical findings: clinically significant abnormal physical findings which could&#xD;
             interfere with the objectives of the study;&#xD;
&#xD;
          3. Laboratory analyses: clinically significant abnormal laboratory values indicative of&#xD;
             physical illness;&#xD;
&#xD;
          4. Allergy: ascertained or presumptive hypersensitivity to the active principle and/or&#xD;
             formulations' ingredients or related drugs, namely non-steroidal anti-inflammatory&#xD;
             agents (NSAIDs); history of anaphylaxis to drugs or allergic reactions in general,&#xD;
             which the investigator considers may affect the outcome of the study;&#xD;
&#xD;
          5. Diseases: history of significant renal, hepatic, gastrointestinal (in particular&#xD;
             gastroduodenal ulcer and bleeding), cardiovascular, respiratory (in particular&#xD;
             asthma), skin, haematological, endocrine or neurological diseases that may interfere&#xD;
             with the aim of the study;&#xD;
&#xD;
          6. Medications: medications, including over the counter (OTC) medications and herbal&#xD;
             products for 2 weeks before the start of the study, in particular ibuprofen. Hormonal&#xD;
             contraceptives for females are allowed;&#xD;
&#xD;
          7. Investigative drug studies: participation in the evaluation of any investigational&#xD;
             product in the 3 months before this study, calculated from the first day of the month&#xD;
             following the last visit of the previous study;&#xD;
&#xD;
          8. Blood donation: blood donations in the 3 months before this study;&#xD;
&#xD;
          9. Drug, alcohol, caffeine, tobacco: history of drug, alcohol [&gt;1 drink/day for females&#xD;
             and &gt;2 drinks/day for males, defined according to United States Department of&#xD;
             Agriculture Dietary Guidelines 2010], caffeine (&gt;5 cups coffee/tea/day) or tobacco&#xD;
             abuse (&gt;=10 cigarettes/day); daily use of distilled spirits;&#xD;
&#xD;
         10. Drug test: positive result at the drug test at screening or day-1;&#xD;
&#xD;
         11. Alcohol test: positive alcohol breath test at day -1;&#xD;
&#xD;
         12. Diet: abnormal diets (&lt;1600 or &gt;3500 kcal/day) or substantial changes in eating habits&#xD;
             in the 4 weeks before this study, vegetarians;&#xD;
&#xD;
         13. Pregnancy (females only): positive or missing pregnancy test at screening or day -1,&#xD;
             pregnant or lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Milko Radicioni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cross Research S.A.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CROSS Research S.A., Phase I Unit, Via F.A. Giorgioli 14 Phone: Fax: +41.91.63.00.511 Email:</name>
      <address>
        <city>Arzo</city>
        <zip>CH-6864</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>June 17, 2015</study_first_submitted>
  <study_first_submitted_qc>June 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2015</study_first_posted>
  <last_update_submitted>June 23, 2015</last_update_submitted>
  <last_update_submitted_qc>June 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>MOMENTACT</keyword>
  <keyword>ibuprofen 400 mg</keyword>
  <keyword>oral</keyword>
  <keyword>granules</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

